Poziotinib Induces Responses in EGFR Exon 20+ NSCLC
home / oncclub / poziotinib-induces-responses-in-egfr-exon-20-nsclc
Yasir Y. Elamin, MD, discusses findings from a phase 2 study (NCT03066206), which found that poziotinib induced an investigator-assessed overall response rate of 32% in patients with non–small cell lung cancer harboring EGFR exon 20 mutations.